Yahoo
NasdaqCM - Nasdaq Real Time Price USD

Context Therapeutics Inc. (CNTX)

2.2100 -0.0500 (-2.21%)
As of 12:52:30 PM EDT. Market Open.
Trade CNTX on Coinbase
Chart Range Bar
Loading chart for CNTX
  • Previous Close 2.2600
  • Open 2.2600
  • Bid 1.6300 x 200
  • Ask 2.8100 x 200
  • Day's Range 2.1700 - 2.3100
  • 52 Week Range 0.4900 - 3.6200
  • Volume 811,470
  • Avg. Volume 1,173,639
  • Market Cap (intraday) 203.053M
  • Beta (5Y Monthly) 1.83
  • PE Ratio (TTM) --
  • EPS (TTM) -0.3800
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.00

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

www.contexttherapeutics.com

15

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: CNTX

Trailing total returns as of 4/27/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CNTX
50.34%
S&P 500 (^GSPC)
4.66%

1-Year Return

CNTX
135.11%
S&P 500 (^GSPC)
29.67%

3-Year Return

CNTX
281.03%
S&P 500 (^GSPC)
73.25%

5-Year Return

CNTX
50.23%
S&P 500 (^GSPC)
71.12%

Earnings Trends: CNTX

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -13.03M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-10M
-5M
0

Analyst Insights: CNTX

View More

Analyst Price Targets

4.00
6.00 Average
2.2100 Current
9.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 3/24/2026
Analyst D. Boral Capital
Rating Action Maintains
Rating Buy
Price Action Maintains
Price Target 9 -> 9

Statistics: CNTX

View More

Valuation Measures

Annual
As of 4/24/2026
  • Market Cap

    207.65M

  • Enterprise Value

    141.76M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    3.43

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -29.79%

  • Return on Equity (ttm)

    -46.39%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -36.12M

  • Diluted EPS (ttm)

    -0.3800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    66M

  • Total Debt/Equity (mrq)

    0.19%

  • Levered Free Cash Flow (ttm)

    -19.13M

Compare To: CNTX

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: CNTX

Fair Value

2.2100 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: